Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study

J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e757-e759. doi: 10.1111/jdv.18889. Epub 2023 Feb 6.

Authors

Elena Pezzolo^{1

2}, MariaTeresa Rossi³, Francesca Caroppo⁴, Tommaso Bianchelli⁵, Anna Belloni Fortina⁴, Alfredo Giacchetti⁵, Piergiacomo Calzavara Pinton³, Luigi Naldi^{1

2}

Affiliations

¹ Department of Dermatology, San Bortolo Hospital, Vicenza, Italy.
² Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.
³ Dermatology Department, University of Brescia, Brescia, Italy.
⁴ Dermatology Department, University of Padua, Padua, Italy.
⁵ Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, INRCA-IRCCS Hospital, Ancona, Italy.

PMID: 36662631
DOI: 10.1111/jdv.18889

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / therapeutic use
Dermatitis, Atopic* / drug therapy
Humans
Prospective Studies
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal